Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis

[1]  M. Zálešák,et al.  Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study , 2021, Multiple sclerosis.

[2]  C. Cameron,et al.  Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. , 2020, Journal of comparative effectiveness research.

[3]  Jeffrey A. Cohen,et al.  Ofatumumab versus Teriflunomide in Multiple Sclerosis. , 2020, The New England journal of medicine.

[4]  P. Iwanowski,et al.  Role of B cells and antibodies in multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[5]  J. Standing,et al.  Pharmacodynamics of rituximab on B lymphocytes in paediatric patients with autoimmune diseases , 2019, British journal of clinical pharmacology.

[6]  H. Önder.  Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis , 2019, Turkish Journal Of Neurology.

[7]  R. Milo.  Therapies for multiple sclerosis targeting B cells , 2019, Croatian medical journal.

[8]  J. Tolson,et al.  Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study , 2019, Neurology.

[9]  Martin S. Weber,et al.  The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders , 2019, Front. Immunol..

[10]  S. Hauser,et al.  B-Cell Therapies in Multiple Sclerosis. , 2019, Cold Spring Harbor perspectives in medicine.

[11]  A. Bar-Or,et al.  Reassessing B cell contributions in multiple sclerosis , 2018, Nature Immunology.

[12]  B. Meibohm,et al.  Pharmacokinetics of Monoclonal Antibodies , 2017, CPT: pharmacometrics & systems pharmacology.

[13]  A. Traboulsee,et al.  Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.

[14]  PH van der Graaf,et al.  A Tutorial on Target-Mediated Drug Disposition (TMDD) Models , 2015, CPT: pharmacometrics & systems pharmacology.

[15]  A. Hagenbeek,et al.  Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis , 2014, Journal of clinical pharmacology.

[16]  F Mentré,et al.  Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics , 2014, CPT: pharmacometrics & systems pharmacology.

[17]  C. Klein,et al.  Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties , 2013, mAbs.

[18]  D. Tough,et al.  B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. , 2005, Blood.

[19]  F. Barkhof,et al.  Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials , 1999, Journal of the Neurological Sciences.